Cargando…

376. COVID-19 Severity in HIV+ Patients Receiving Tenofovir

BACKGROUND: Early in the COVID-19 pandemic, tenofovir (TAF/TDF) was identified as a potential agent for SARS-CoV-2 due to binding to RNA-dependent RNA polymerase similarly to remdesivir. This led to the hypothesis that TAF/TDF may be lessening the severity and improving outcomes of COVID-19 infectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Homsi, Nora, Vermeulen, Kendra, Snyder, Mitchell, Cennimo, David J, Sonyey, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776174/ http://dx.doi.org/10.1093/ofid/ofaa439.571

Ejemplares similares

853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US
por: Oglesby, Alan, et al.
Publicado: (2021)

1041. Tenofovir alafenamide associated weight change in persons living with HIV
por: Crowder, Carlysle E, et al.
Publicado: (2020)

280. Burden of Hyperglycemia in Patients Receiving Dexamethasone for Severe COVID-19
por: Fetters, Kirk B, et al.
Publicado: (2021)

MED12/376: Microbiology and the Hospital Intranet
por: Perera, B
Publicado: (1999)

376. Sensitivity and Specificity of the WHO Probable SARS-CoV-2 Case Definition Among Symptomatic Healthcare Personnel
por: Nguyen, Han, et al.
Publicado: (2021)

1047. Weight change associated with switching to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed people with HIV
por: Vo, Daniel, et al.
Publicado: (2020)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

1614. Efficacy and Safety of Adjusted Renal Dosing of Tenofovir DF Versus Abacavir Switching in HIV Patients with Decreased Glomerular Filtration Rate After Receiving Tenofovir DF-Based Regimen
por: Yamasmith, Eakkawit, et al.
Publicado: (2023)

P376: Dirty bedpans and MDRO: partners in crime?
por: Van Knippenberg-Gordebeke, GG
Publicado: (2013)

1014. Factors Associated with Switching from Tenofovir Diproxil Phosphate to a Tenofovir Alafenamide Based Regimen in a Cohort with Unrestricted Access to Care and Medications
por: Ganesan, Anuradha, et al.
Publicado: (2020)

Retreatment of Chronic HCV Infection after Second Generation DAA Failure in Patients in the NJ VA Healthcare System
por: Stawarz, Kimberly, et al.
Publicado: (2017)

376. Predictive Model for Fluconazole Resistance in Patient With Candida Bloodstream Infection
por: Aljorayid, Abdullah, et al.
Publicado: (2018)

376. Effect of Parasitic Infections on Gut Epithelial Barrier and Immune Activation among Foreign-Born HIV-infected Patients
por: Reimer-McAtee, Melissa, et al.
Publicado: (2019)

11. People Living with HIV During the COVID-19 Pandemic: Who Did (or Did Not) Receive Annual Influenza Vaccination?
por: Kahal, Deborah A, et al.
Publicado: (2021)

The effect of tenofovir on renal function in HIV-positive pregnant women
por: Flanagan, Stuart, et al.
Publicado: (2014)

1044. The Incidence and Severity of Drug interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients
por: Schafer, Jason J, et al.
Publicado: (2020)

839. Examining the Effects of HIV Infection on Severity of Outcomes in Those with COVID-19
por: Parkinson, Melissa, et al.
Publicado: (2021)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

P376: VENO-OCCLUSIVE DISEASE RISK AND OTHER OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: de Lima, Marcos, et al.
Publicado: (2023)

MINOS: Bt 376 - 599 ext - 376 ext - AP (100)
Publicado: (1991)

470. Relapsing COVID-19 Pneumonia in Patients Receiving Rituximab Therapy
por: Gallagher, Jolie, et al.
Publicado: (2021)

Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens
por: Wohl, David A, et al.
Publicado: (2017)

1551. Changes in Glomerular Filtration Rate after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis
por: Rivera, Adovich, et al.
Publicado: (2023)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

547. Risk Factors Associated with 30-Day Mortality in a Large Cohort of Patients who Received Remdesivir and Corticosteroids for Severe COVID-19
por: Gupta, Kartik, et al.
Publicado: (2021)

629. High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in African American Adults with HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence
por: Andreatta, Kristen, et al.
Publicado: (2021)

1012. Efficacy, safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected virologically-suppressed older adults in a real-world setting
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2020)

High Tenofovir Failure Rates in an Emerging, Non-B Subtype HIV Epidemic
por: Salvana, Edsel Maurice, et al.
Publicado: (2017)

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants
por: Snedecor, Sonya J, et al.
Publicado: (2021)

400. Secondary Infections in COVID-19 Patients Receiving Tocilizumab in a Community Hospital
por: Usiak, Shauna, et al.
Publicado: (2020)

107. Impact of Switching to an Antiretroviral Regimen Containing Tenofovir Alafenamide on Weight Gain and Development of Metabolic Side Effects
por: Darnell, Julia, et al.
Publicado: (2020)

PM376. Mountain-cultivated ginseng attenuates phencyclidine (PCP)-induced schizophrenia-like psychosis in mice
por: Tran, The-Vinh, et al.
Publicado: (2016)

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis
por: Eron, Joseph J, et al.
Publicado: (2020)

Intracellular tenofovir-diphosphate accumulation in an HIV-infected patient with Fanconi syndrome and osteomalacia
por: Haverkort, ME, et al.
Publicado: (2010)

1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
por: Brar, Indira, et al.
Publicado: (2020)

80. The Utility of Cultures for Isolated Fevers in Patients with Influenza or COVID-19 Receiving Extracorporeal Membrane Oxygenation
por: Marcus, Joseph E, et al.
Publicado: (2021)

341. Evaluation of Antimicrobial Use and Prescribing Patterns During the COVID-19 Pandemic in Patients Receiving Tocilizumab
por: Barsoum, Barbara, et al.
Publicado: (2021)

Travaux au bâtiment 376
Publicado: (1992)

519. Immune responses and COVID-19 severity
por: salvatore, mirella, et al.
Publicado: (2020)

Tenofovir use is associated with low vitamin D levels in a Spanish HIV cohort
por: Cervero, M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tihgvbskk7cpq7og0uc139ufd8